source
- Eli Lilly’s Zepbound plus amylin candidate shows 23% weight loss in phase 2 trial, but many patients stopped treatmentEli Lilly tested a combination of its GLP‑1 obesity drug Zepbound with the amylin‑targeting candidate eloralintide in a mid‑stage study of people with obesity and type 2 diabetes. After 48 weeks,…
- UnitedHealth lawsuit proceeds as judge rejects motion to dismiss earnings manipulation claimsA federal judge allowed an investor lawsuit against UnitedHealth Group to continue, rejecting the company's request to throw out the case. The suit alleges UnitedHealth inflated its 2024 earnings…